Avner Thaler

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1259108/publications.pdf

Version: 2024-02-01

51 papers	1,590 citations	331259 21 h-index	315357 38 g-index
51 all docs	51 docs citations	51 times ranked	1951 citing authors

#	Article	IF	Citations
1	Glucocerebrosidase Activity is not Associated with Parkinson's Disease Risk or Severity. Movement Disorders, 2022, 37, 190-195.	2.2	19
2	Glucocerebrosidase Activity Is Not Associated with Parkinson's Disease Risk or Severity. Movement Disorders, 2022, 37, 651-652.	2.2	4
3	Aberrant dopamine transporter and functional connectivity patterns in LRRK2 and GBA mutation carriers. Npj Parkinson's Disease, 2022, 8, 20.	2.5	5
4	Long-Term Persistence and Monotherapy with Device-Aided Therapies: A Retrospective Analysis of an Israeli Cohort of Patients with Advanced Parkinsonâ€™s Disease. Advances in Therapy, 2022, , 1.	1.3	2
5	PARK16 locus: Differential effects of the non-coding rs823114 on Parkinsonâ€™s disease risk, RNA expression, and DNA methylation. Journal of Genetics and Genomics, 2021, 48, 341-345.	1.7	4
6	The Effect of GBA Mutations and APOE Polymorphisms on Dementia with Lewy Bodies in Ashkenazi Jews. Journal of Alzheimer's Disease, 2021, 80, 1221-1229.	1.2	12
7	Association of Dual LRRK2 G2019S and GBA Variations With Parkinson Disease Progression. JAMA Network Open, 2021, 4, e215845.	2.8	38
8	The GBA-370Rec Parkinson's disease risk haplotype harbors a potentially pathogenic variant in the mitochondrial gene SLC25A44. Molecular Genetics and Metabolism, 2021, 133, 109-112.	0.5	2
9	Detecting Sensitive Mobility Features for Parkinson's Disease Stages Via Machine Learning. Movement Disorders, 2021, 36, 2144-2155.	2.2	40
10	Mutations in GBA and LRRK2 Are Not Associated with Increased Inflammatory Markers. Journal of Parkinson's Disease, 2021, 11, 1285-1296.	1.5	16
11	C9orf72-G4C2 Intermediate Repeats and Parkinsonâ€™s Disease; A Data-Driven Hypothesis. Genes, 2021, 12, 1210.	1.0	2
12	Whole brain and deep gray matter structure segmentation: Quantitative comparison between MPRAGE and MP2RAGE sequences. PLoS ONE, 2021, 16, e0254597.	1.1	7
13	Quantitative digital clock drawing test as a sensitive tool to detect subtle cognitive impairments in early stage Parkinson's disease. Parkinsonism and Related Disorders, 2021, 90, 84-89.	1.1	8
14	Biochemical markers for severity and risk in GBA and LRRK2 Parkinsonâ€™s disease. Journal of Neurology, 2021, 268, 1517-1525.	1.8	4
15	Metabolic syndrome does not influence the phenotype of LRRK2 and GBA related Parkinsonâ€™s disease. Scientific Reports, 2020, 10, 9329.	1.6	19
16	Low cerebrospinal fluid volume and the risk for post-lumbar puncture headaches. Journal of the Neurological Sciences, 2020, 417, 117059.	0.3	3
17	Tossing and Turning in Bed: Nocturnal Movements in Parkinson's Disease. Movement Disorders, 2020, 35, 959-968.	2.2	34
18	A Possible Modifying Effect of the G2019S Mutation in the LRRK2 Gene on GBA Parkinson's Disease. Movement Disorders, 2020, 35, 1249-1253.	2.2	27

#	Article	IF	Citations
19	Altered reward-related neural responses in non-manifesting carriers of the Parkinson disease related LRRK2 mutation. Brain Imaging and Behavior, 2019, 13, 1009-1020.	1.1	20
20	Revisiting the non-Gaucher-GBA-E326K carrier state: Is it sufficient to increase Parkinson's disease risk?. Molecular Genetics and Metabolism, 2019, 128, 470-475.	0.5	25
21	Hierarchical Data-Driven Analysis of Clinical Symptoms Among Patients With Parkinson's Disease. Frontiers in Neurology, 2019, 10, 531.	1.1	13
22	Network abnormalities among nonâ€•manifesting Parkinson disease related LRRK2 mutation carriers. Human Brain Mapping, 2019, 40, 2546-2555.	1.9	16
23	Distinguishing Dementia With Lewy Bodies From Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2019, 33, 279-281.	0.6	2
24	Single center experience with medical cannabis in Gilles de la Tourette syndrome. Parkinsonism and Related Disorders, 2019, 61, 211-213.	1.1	22
25	Repeated Intravenous Amantadine Infusions in Advanced Parkinsonism: Experience of a Large Movement Disorder Center. Israel Medical Association Journal, 2019, 21, 812-816.	0.1	1
26	Application of the Movement Disorder Society prodromal criteria in healthy G2019Sâ€‹LRRK2 carriers. Movement Disorders, 2018, 33, 966-973.	2.2	44
27	Progression in the LRRK2-Associated Parkinson Disease Population. JAMA Neurology, 2018, 75, 312.	4.5	109
28	Survival rates among Parkinson's disease patients who carry mutations in the LRRK2 and GBA genes. Movement Disorders, 2018, 33, 1656-1660.	2.2	14
29	Structural and Functional MRI in Familial Parkinson's Disease. International Review of Neurobiology, 2018, 142, 261-287.	0.9	4
30	Parkinson's disease phenotype is influenced by the severity of the mutations in the GBA gene. Parkinsonism and Related Disorders, 2018, 55, 45-49.	1.1	90
31	Cerebral Imaging Markers of GBA and LRRK2 Related Parkinsonâ€™s Disease and Their First-Degree Unaffected Relatives. Brain Topography, 2018, 31, 1029-1036.	0.8	23
32	A â€œdoseâ€•effect of mutations in the GBA gene on Parkinson's disease phenotype. Parkinsonism and Related Disorders, 2017, 36, 47-51.	1.1	78
33	Robust inter-subject audiovisual decoding in functional magnetic resonance imaging using high-dimensional regression. NeuroImage, 2017, 163, 244-263.	2.1	11
34	Validation of the Hebrew version of the Movement Disorder Societyâ€”Unified Parkinson's Disease Rating Scale. Parkinsonism and Related Disorders, 2017, 45, 7-12.	1.1	9
35	Reduced mind wandering in patients with Parkinson's disease. Parkinsonism and Related Disorders, 2017, 44, 38-43.	1.1	5
36	A cognitive fMRI study in non-manifesting LRRK2 and GBA carriers. Brain Structure and Function, 2017, 222, 1207-1218.	1.2	22

#	Article	IF	Citations
37	DaT-SPECT assessment depicts dopamine depletion among asymptomatic G2019S LRRK2 mutation carriers. PLoS ONE, 2017, 12, e0175424.	1.1	27
38	A Personalized Approach to Parkinsonâ€™s Disease Patients Based on Founder Mutation Analysis. Frontiers in Neurology, 2016, 7, 71.	1.1	21
39	Arm swing as a potential new prodromal marker of Parkinson's disease. Movement Disorders, 2016, 31, 1527-1534.	2.2	136
40	Intact working memory in nonâ€manifesting <scp>LRRK</scp>2 carriers â€“ an <scp>fMRI</scp> study. European Journal of Neuroscience, 2016, 43, 106-112.	1.2	16
41	Effects of Aging on Arm Swing during Gait: The Role of Gait Speed and Dual Tasking. PLoS ONE, 2015, 10, e0136043.	1.1	63
42	Nonmotor symptoms in healthy Ashkenazi Jewish carriers of the G2019S mutation in the LRRK2 gene. Movement Disorders, 2015, 30, 981-986.	2.2	52
43	Reorganization of corticostriatal circuits in healthy G2019S LRRK2 carriers. Neurology, 2015, 84, 399-406.	1.5	66
44	A voxelâ€based morphometry and diffusion tensor imaging analysis of asymptomatic Parkinson's diseaseâ€related G2019S LRRK2 mutation carriers. Movement Disorders, 2014, 29, 823-827.	2.2	20
45	Fall risk and gait in Parkinson's disease: The role of the LRRK2 G2019S mutation. Movement Disorders, 2013, 28, 1683-1690.	2.2	82
46	Parkinson disease phenotype in Ashkenazi jews with and without LRRK2 G2019S mutations. Movement Disorders, 2013, 28, 1966-1971.	2.2	131
47	Neural correlates of executive functions in healthy G2019S LRRK2 mutation carriers. Cortex, 2013, 49, 2501-2511.	1.1	42
48	Lower cognitive performance in healthy G2019S LRRK2 mutation carriers. Neurology, 2012, 79, 1027-1032.	1.5	75
49	Cerebral pathological and compensatory mechanisms in the premotor phase of leucine-rich repeat kinase 2 parkinsonism. Brain, 2012, 135, 3687-3698.	3.7	33
50	Appreciation of humor is decreased among patients with Parkinsonâ€™s disease. Parkinsonism and Related Disorders, 2012, 18, 144-148.	1.1	18
51	The LRRK2 G2019S mutation as the cause of Parkinsonâ€™s disease in Ashkenazi Jews. Journal of Neural Transmission, 2009, 116, 1473-1482.	1.4	54